Published in Methods Enzymol on January 01, 2005
pHLIP-mediated translocation of membrane-impermeable molecules into cells. Chem Biol (2009) 1.16
Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug Chem (2012) 0.99
Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides. Biomacromolecules (2006) 0.87
Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes. Antimicrob Agents Chemother (2013) 0.80
Phospholipid-Nucleic Acid Complexation: Biomolecular Energetics of DNA-Mg(2+)-Phosphatidylcholine Ternary Complex Formation, Compaction and Relevance as Lipoplex Formulation. Int J Biomed Sci (2006) 0.75
Drug delivery systems: entering the mainstream. Science (2004) 9.27
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev (2012) 4.30
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl (2012) 1.87
The liposomal formulation of doxorubicin. Methods Enzymol (2005) 1.62
Liposomal nanomedicines. Expert Opin Drug Deliv (2008) 1.26
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther (2011) 1.23
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids (2012) 1.16
Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir (2012) 1.13
Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release (2005) 1.12
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Liposomal nanomedicines: an emerging field. Toxicol Pathol (2008) 1.01
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces (2012) 0.93
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain. Mol Ther Nucleic Acids (2013) 0.92
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release (2005) 0.91
Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta (2007) 0.90
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer (2012) 0.90
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol (2009) 0.90
Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol (2007) 0.89
Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. Bioconjug Chem (2009) 0.88
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano (2015) 0.88
Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids. Biochim Biophys Acta (2003) 0.87
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release (2010) 0.87
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res (2008) 0.86
Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol (2002) 0.86
Advances in Lipid Nanoparticles for siRNA Delivery. Pharmaceutics (2013) 0.85
Tunable pH-sensitive liposomes. Methods Enzymol (2004) 0.83
Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem J (2007) 0.83
Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol (2005) 0.82
Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents. Mol Membr Biol (2005) 0.82
Triggered release of doxorubicin following mixing of cationic and anionic liposomes. Biochim Biophys Acta (2002) 0.81
Calcium enhances the transfection potency of stabilized plasmid-lipid particles. Anal Biochem (2005) 0.80
Distal cationic poly(ethylene glycol) lipid conjugates in large unilamellar vesicles prepared by extrusion enhance liposomal cellular uptake. J Liposome Res (2004) 0.80
Development of high-concentration lipoplexes for in vivo gene function studies in vertebrate embryos. Dev Dyn (2011) 0.79
Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine (2012) 0.78
The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine. J Gene Med (2009) 0.78
Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine (2012) 0.77
Capillary electrophoresis frontal analysis for characterization of alphavbeta3 integrin binding interactions. Anal Chem (2008) 0.77
Synthesis and properties of novel tetraalkyl cationic lipids. Bioconjug Chem (2002) 0.77
IGFBP2 is neither sufficient nor necessary for the physiological actions of leptin on glucose homeostasis in male ob/ob mice. Endocrinology (2014) 0.76
Investigation of factors responsible for cell line cytoplasmic expression differences. BMC Mol Biol (2005) 0.75
Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications. Methods Mol Biol (2014) 0.75
The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN. J Drug Target (2008) 0.75
Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles. Nanoscale (2017) 0.75